SPAC Files Definitive Proxy for 6-Month Extension to Avoid Liquidation; Shareholders Offered $10.84 Redemption

summarizeSummary

GP-Act III Acquisition Corp. filed a definitive proxy statement to extend its business combination deadline by six months to November 13, 2026, with shareholders having the option to redeem shares at $10.84 each.

check_boxKey Events

• Shareholder Meeting Scheduled

  An Extraordinary General Meeting is scheduled for April 29, 2026, for shareholders to vote on critical proposals.

• Extension Proposals Finalized

  The company seeks to extend its business combination deadline and the Trust Account liquidation date from May 13, 2026, to November 13, 2026, a six-month extension.

• Shareholder Redemption Option

  Public shareholders can redeem their Class A ordinary shares for approximately $10.84 per share, based on the Trust Account balance as of March 30, 2026. This redemption price is slightly above the current market price of $10.82.

• Ongoing Business Combination Negotiations

  The company is currently negotiating a potential business combination, and the extension is sought to allow more time to finalize and consummate this deal.

auto_awesomeAnalysis

This definitive proxy statement (DEF 14A) is a critical development for GP-Act III Acquisition Corp., a SPAC facing a May 13, 2026, deadline to complete a business combination or liquidate. Following a preliminary filing, this document finalizes the terms for a shareholder vote on April 29, 2026, to extend this deadline by six months to November 13, 2026. The company is actively negotiating a potential business combination, and this extension is essential to provide the necessary time to finalize and seek approval for that deal. Public shareholders are offered redemption rights at approximately $10.84 per share, which is slightly above the current market price of $10.82, offering a clear exit option. However, significant redemptions could reduce the capital available for any future business combination, posing a risk to the SPAC's ability to close a deal. This filing directly addresses the 'going concern' doubt raised in the company's recent 10-K, making the outcome of the shareholder vote paramount for the company's survival.